Investigating how SETD7 helps prevent prostate cancer progression and therapy resistance
Noncanonical activities of SETD7 in preventing prostate cancer progression andtherapy resistance
This study is looking at how a protein called SETD7 affects prostate cancer and how it might change the way well-known treatments work, with the goal of finding better options for patients dealing with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Massachusetts Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11049260 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the SETD7 protein in prostate cancer, particularly how it influences the effectiveness of androgen deprivation therapies. The study examines the mechanisms by which SETD7 regulates other proteins involved in cancer progression and resistance to treatment. By analyzing cancer cells and their response to therapies, the research aims to uncover new insights that could lead to improved treatment strategies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are undergoing or have undergone androgen deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who do not have androgen receptor-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance the effectiveness of existing prostate cancer treatments.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic regulators like SETD7 in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- University of Massachusetts Boston — Boston, United States (Active)
Researchers
- Principal investigator: Cai, Changmeng — University of Massachusetts Boston
- Study coordinator: Cai, Changmeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.